Coverage for these medications varies widely across plans; while many employers cover GLP-1 for diabetes treatment, fewer ...

Pendulum Therapeutics latest innovation comes in the form of a GLP-1 probiotic, acting as an appetite suppressor and healthy ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk's highly in-demand drugs for diabetes and weight loss, according to a review of patient data published on Monday, the ...

Poor bowel preparation also led to repeat colonoscopies for 18.9% of current GLP-1RA users, compared to 11.1% of controls ...

Recently the U.S. Food and Drug Administration (FDA) issued updated safety warnings for all glucagon-like peptide 1 receptor ...

Novo Nordisk's involve the GLP-1 pathway, while Eli Lilly's treatments activate both GLP-1 and GIP, known as dual GLP-1/GIP ...

The brokerage highlighted that there are several growth opportunities for the company going ahead including the growing CS ...

If you looked solely at its stock price, you might get the idea that Eli Lilly (NYSE: LLY) is having a bit of an off quarter.

Executives from Impact Analytics and Carters Inc. discuss demographic shifts, changing compositions, weight loss drugs and ...